The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Witthuhn, B. A., Quelle, F. W., Silvennoinen, O., Yi, T., Tang, B., Miura, O., & Ihle, J. N. (1993) · Cell · doi:10.1016/0092-8674(93)90414-l · Cited by 1,194
A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia
Lacronique, V., Boureux, A., Della Valle, V., Poirel, H., Quang, C. T., Mauchauffé, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., et al. (1997) · Science · doi:10.1126/science.278.5341.1309 · Cited by 791
Self-citationPolycythemia vera: myths, mechanisms, and management
Spivak, J. L. (2002) · Blood · doi:10.1182/blood-2001-12-0349 · Cited by 463
Bone-Marrow Responses in Polycythemia Vera
(1974) · New England Journal of Medicine · doi:10.1056/nejm197406132902419 · Cited by 420
Dumoutier, L., Van Roost, E., Colau, D., & Renauld, J.-C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170291697 · Cited by 365
Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain
Saharinen, P., Takaluoma, K., & Silvennoinen, O. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.10.3387-3395.2000 · Cited by 365
Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera
Kralovics, R., Guan, Y., & Prchal, J. T. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(01)00789-5 · Cited by 300
Huang, L. J.-S., Constantinescu, S. N., & Lodish, H. F. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00401-4 · Cited by 294
Self-citationMutation in the Jak Kinase JH2 Domain Hyperactivates Drosophila and Mammalian Jak-Stat Pathways
Luo, H., Rose, P., Barber, D., Hanratty, W. P., Lee, S., Roberts, T. M., D’Andrea, A. D., & Dearolf, C. R. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1562 · Cited by 242
A JAK1/JAK2 Chimera Can Sustain Alpha and Gamma Interferon Responses
Kohlhuber, F. K., Rogers, N. C., Watling, D., Feng, J., Guschin, D., Briscoe, J., Witthuhn, B. A., Kotenko, S. V., Pestka, S., Stark, G. R., et al. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.2.695 · Cited by 218
Cited by
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311347 · Cited by 2,003
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
“Grade 1 50 (34) 6 (4) 29 (20) 12 (8) 3 (2)”
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1312542 · Cited by 1,756
Yoder, M. C., Mead, L. E., Prater, D., Krier, T. R., Mroueh, K. N., Li, F., Krasich, R., Temm, C. J., Prchal, J. T., & Ingram, D. A. (2007) · Blood · doi:10.1182/blood-2006-08-043471 · Cited by 1,477
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,449
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,276
Mechanisms and consequences of Jak–STAT signaling in the immune system
Villarino, A. V., Kanno, Y., & O'Shea, J. J. (2017) · Nature Immunology · doi:10.1038/ni.3691 · Cited by 1,221
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149
“The dramatic discovery that the mutations of Jak2 underlie nearly all cases of PV and many cases of ET and MPD provided a rationale for the use of Jak2 inhibitors in this setting (15).”
BackgroundAdvances in understanding cancer genomes through second-generation sequencing
Meyerson, M., Gabriel, S., & Getz, G. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2841 · Cited by 1,116
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Pardanani, A. D., Levine, R. L., Lasho, T., Pikman, Y., Mesa, R. A., Wadleigh, M., Steensma, D. P., Elliott, M. A., Wolanskyj, A. P., Hogan, W. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-018879 · Cited by 1,056
Interplay between inflammation and thrombosis in cardiovascular pathology
Stark, K., & Massberg, S. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00552-1 · Cited by 1,033
Tefferi, A., & Vardiman, J. W. (2008) · Leukemia · doi:10.1038/sj.leu.2404955 · Cited by 1,002
High-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., DeBiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 988
The molecular details of cytokine signaling via the JAK/STAT pathway
Morris, R., Kershaw, N. J., & Babon, J. J. (2018) · Protein Science · doi:10.1002/pro.3519 · Cited by 943
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
The Myeloproliferative Disorders
Campbell, P. J., & Green, A. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra063728 · Cited by 915
Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H. M., Barbui, T., Hanson, C. A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., et al. (2007) · Blood · doi:10.1182/blood-2007-04-083501 · Cited by 862
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Jones, A. V. (2005) · Blood · doi:10.1182/blood-2005-03-1320 · Cited by 843
Quintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Force, T., Krause, D. S., & Van Etten, R. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2106 · Cited by 801
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210039 · Cited by 727
Tefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A. M., Rodeghiero, F., Randi, M. L., Vaidya, R., Cazzola, M., Rambaldi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.163 · Cited by 700
Campbell, P. J., Scott, L. M., Buck, G., Wheatley, K., East, C. L., Marsden, J. T., Duffy, A., Boyd, E. M., Bench, A. J., Scott, M. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67785-9 · Cited by 653
Interleukin-6: designing specific therapeutics for a complex cytokine
Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643
Barbui, T., Thiele, J., Gisslinger, H., Kvasnicka, H. M., Vannucchi, A. M., Guglielmelli, P., Orazi, A., & Tefferi, A. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0054-y · Cited by 641
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Lundberg, P., Karow, A., Nienhold, R., Looser, R., Hao-Shen, H., Nissen, I., Girsberger, S., Lehmann, T., Passweg, J., Stern, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-537167 · Cited by 634
JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
Dawson, M. A., Bannister, A. J., Göttgens, B., Foster, S. D., Bartke, T., Green, A. R., & Kouzarides, T. (2009) · Nature · doi:10.1038/nature08448 · Cited by 622
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
Vainchenker, W., & Kralovics, R. (2017) · Blood · doi:10.1182/blood-2016-10-695940 · Cited by 616
Self-citationIdentification of an Acquired JAK2 Mutation in Polycythemia Vera
Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S. B., & Zhao, Z. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500138200 · Cited by 615
Barbui, T., Finazzi, G., Carobbio, A., Thiele, J., Passamonti, F., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., Bertozzi, I., et al. (2012) · Blood · doi:10.1182/blood-2012-07-444067 · Cited by 604
Rumi, E., Pietra, D., Ferretti, V., Klampfl, T., Harutyunyan, A. S., Milosevic, J. D., Them, N. C. C., Berg, T., Elena, C., Casetti, I. C., et al. (2014) · Blood · doi:10.1182/blood-2013-11-539098 · Cited by 602
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Levine, R. L., Pardanani, A., Tefferi, A., & Gilliland, D. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2210 · Cited by 588
Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
Maxson, J. E., Gotlib, J., Pollyea, D. A., Fleischman, A. G., Agarwal, A., Eide, C. A., Bottomly, D., Wilmot, B., McWeeney, S. K., Tognon, C. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214514 · Cited by 571
The molecular mechanisms that control thrombopoiesis
Kaushansky, K. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26674 · Cited by 570
JAK mutations in high-risk childhood acute lymphoblastic leukemia
Mullighan, C. G., Zhang, J., Harvey, R. C., Collins-Underwood, J. R., Schulman, B. A., Phillips, L. A., Tasian, S. K., Loh, M. L., Su, X., Liu, W., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811761106 · Cited by 562
Exome-wide association study of plasma lipids in >300,000 individuals
Charge Diabetes Working Group, Liu, D. J., The EPIC-InterAct Consortium, EPIC-CVD Consortium, GOLD Consortium, Program, V. M. V., Peloso, G. M., Yu, H., Butterworth, A. S., Wang, X., et al. (2017) · Nature Genetics · doi:10.1038/ng.3977 · Cited by 540
Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.69 · Cited by 534
JAK/STAT signaling in hematological malignancies
Vainchenker, W., & Constantinescu, S. N. (2013) · Oncogene · doi:10.1038/onc.2012.347 · Cited by 528
Self-citationWernig, G., Mercher, T., Okabe, R., Levine, R. L., Lee, B. H., & Gilliland, D. G. (2006) · Blood · doi:10.1182/blood-2005-12-4824 · Cited by 483
Priming of the neutrophil respiratory burst: role in host defense and inflammation
El‐Benna, J., Hurtado‐Nedelec, M., Marzaioli, V., Marie, J., Gougerot‐Pocidalo, M., & Dang, P. M. (2016) · Immunological Reviews · doi:10.1111/imr.12447 · Cited by 478
Biology and significance of the JAK/STAT signalling pathways
Kiu, H., & Nicholson, S. E. (2012) · Growth Factors · doi:10.3109/08977194.2012.660936 · Cited by 470
“Since its discovery in 2005, most of the research has focused on the JAK2 V617F mutation (Baxter et al. 2005; James et al. 2005; Kralovics et al. 2005; Levine et al. 2005).”
Steensma, D. P., Dewald, G. W., Lasho, T. L., Powell, H. L., McClure, R. F., Levine, R. L., Gilliland, D. G., & Tefferi, A. (2005) · Blood · doi:10.1182/blood-2005-03-1183 · Cited by 466
The sequences of 150,119 genomes in the UK Biobank
Halldorsson, B. V., Eggertsson, H. P., Moore, K. H. S., Hauswedell, H., Eiriksson, O., Ulfarsson, M. O., Palsson, G., Hardarson, M. T., Oddsson, A., Jensson, B. O., et al. (2022) · Nature · doi:10.1038/s41586-022-04965-x · Cited by 448
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Rambaldi, A., Barosi, G., Marchioli, R., Marfisi, R. M., Finazzi, G., Guerini, V., Fabris, F., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064287 · Cited by 449
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms
Arranz, L., Sánchez-Aguilera, A., Martín-Pérez, D., Isern, J., Langa, X., Tzankov, A., Lundberg, P., Muntión, S., Tzeng, Y.-S., Lai, D.-M., et al. (2014) · Nature · doi:10.1038/nature13383 · Cited by 444
MYC Deregulation in Primary Human Cancers
Kalkat, M., De Melo, J., Hickman, K., Lourenco, C., Redel, C., Resetca, D., Tamachi, A., Tu, W., & Penn, L. (2017) · Genes · doi:10.3390/genes8060151 · Cited by 443
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Tiedt, R., Hao-Shen, H., Sobas, M. A., Looser, R., Dirnhofer, S., Schwaller, J., & Skoda, R. C. (2008) · Blood · doi:10.1182/blood-2007-08-107748 · Cited by 440
Lacout, C., Pisani, D. F., Tulliez, M., Gachelin, F. M., Vainchenker, W., & Villeval, J.-L. (2006) · Blood · doi:10.1182/blood-2006-02-002030 · Cited by 435
Self-citationMPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
Beer, P. A., Campbell, P. J., Scott, L. M., Bench, A. J., Erber, W. N., Bareford, D., Wilkins, B. S., Reilly, J. T., Hasselbalch, H. C., Bowman, R., et al. (2008) · Blood · doi:10.1182/blood-2008-01-131664 · Cited by 431
Rampal, R., Al-Shahrour, F., Abdel-Wahab, O., Patel, J. P., Brunel, J.-P., Mermel, C. H., Bass, A. J., Pretz, J., Ahn, J., Hricik, T., et al. (2014) · Blood · doi:10.1182/blood-2014-02-554634 · Cited by 428
Quintás-Cardama, A., Kantarjian, H., Manshouri, T., Luthra, R., Estrov, Z., Pierce, S., Richie, M. A., Borthakur, G., Konopleva, M., Cortes, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6075 · Cited by 428
Tefferi, A., Pardanani, A., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Gangat, N., Finke, C. M., Schwager, S., Mullally, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.47 · Cited by 425
Self-citationPPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy
Hsu, J. I., Dayaram, T., Tovy, A., De Braekeleer, E., Jeong, M., Wang, F., Zhang, J., Heffernan, T. P., Gera, S., Kovacs, J. J., et al. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.10.004 · Cited by 425
“Other genes such as JAK2 skew normal proliferation and differentiation of hematopoietic progenitor cells, resulting in strong expansion (James et al., 2005).”
BackgroundGain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms
Sanada, M., Suzuki, T., Shih, L.-Y., Otsu, M., Kato, M., Yamazaki, S., Tamura, A., Honda, H., Sakata-Yanagimoto, M., Kumano, K., et al. (2009) · Nature · doi:10.1038/nature08240 · Cited by 402
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Pardanani, A., Gotlib, J. R., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R. M., Silverman, M. H., Gilliland, D. G., Shorr, J., & Tefferi, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8021 · Cited by 400
Ye, Z., Zhan, H., Mali, P., Dowey, S., Williams, D. M., Jang, Y.-Y., Dang, C. V., Spivak, J. L., Moliterno, A. R., & Cheng, L. (2009) · Blood · doi:10.1182/blood-2009-04-217406 · Cited by 399
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
Jones, A. V., Chase, A., Silver, R. T., Oscier, D., Zoi, K., Wang, Y. L., Cario, H., Pahl, H. L., Collins, A., Reiter, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.334 · Cited by 399
JAK/STAT signalling in Drosophila: insights into conserved regulatory and cellular functions
Arbouzova, N. I., & Zeidler, M. P. (2006) · Development · doi:10.1242/dev.02411 · Cited by 397
Mullally, A., Lane, S. W., Ball, B., Megerdichian, C., Okabe, R., Al-Shahrour, F., Paktinat, M., Haydu, J. E., Housman, E., Lord, A. M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.015 · Cited by 395
New mutations and pathogenesis of myeloproliferative neoplasms
Vainchenker, W., Delhommeau, F., Constantinescu, S. N., & Bernard, O. A. (2011) · Blood · doi:10.1182/blood-2011-02-292102 · Cited by 395
Self-citationWernig, G., Kharas, M. G., Okabe, R., Moore, S. A., Leeman, D. S., Cullen, D. E., Gozo, M., McDowell, E. P., Levine, R. L., Doukas, J., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.009 · Cited by 390
Grand, F. H., Hidalgo-Curtis, C. E., Ernst, T., Zoi, K., Zoi, C., McGuire, C., Kreil, S., Jones, A., Score, J., Metzgeroth, G., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194548 · Cited by 378
Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis
Smalberg, J. H., Arends, L. R., Valla, D. C., Kiladjian, J.-J., Janssen, H. L. A., & Leebeek, F. W. G. (2012) · Blood · doi:10.1182/blood-2011-09-376517 · Cited by 377
“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
Bousoik, E., & Montazeri Aliabadi, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00287 · Cited by 376
Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
Koppikar, P., Bhagwat, N., Kilpivaara, O., Manshouri, T., Adli, M., Hricik, T., Liu, F., Saunders, L. M., Mullally, A., Abdel-Wahab, O., et al. (2012) · Nature · doi:10.1038/nature11303 · Cited by 370
Jelinek, J., Oki, Y., Gharibyan, V., Bueso-Ramos, C., Prchal, J. T., Verstovsek, S., Beran, M., Estey, E., Kantarjian, H. M., & Issa, J.-P. J. (2005) · Blood · doi:10.1182/blood-2005-05-1800 · Cited by 369
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Longo, G., Pancrazzi, A., Ponziani, V, Bogani, C., Ferrini, P. R., Rambaldi, A., Guerini, V, et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404854 · Cited by 368
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms
Olcaydu, D., Harutyunyan, A., Jäger, R., Berg, T., Gisslinger, B., Pabinger, I., Gisslinger, H., & Kralovics, R. (2009) · Nature Genetics · doi:10.1038/ng.341 · Cited by 362
Kiladjian, J.-J., Cervantes, F., Leebeek, F. W. G., Marzac, C., Cassinat, B., Chevret, S., Cazals-Hatem, D., Plessier, A., Garcia-Pagan, J.-C., Murad, S. D., et al. (2008) · Blood · doi:10.1182/blood-2007-11-125328 · Cited by 361
Self-citationGenetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
Fröhling, S., Scholl, C., Gilliland, D. G., & Levine, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.010 · Cited by 353
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
Renneville, A., Roumier, C., Biggio, V, Nibourel, O., Boissel, N., Fenaux, P., & Preudhomme, C. (2008) · Leukemia · doi:10.1038/leu.2008.19 · Cited by 351
Kilpivaara, O., Mukherjee, S., Schram, A. M., Wadleigh, M., Mullally, A., Ebert, B. L., Bass, A., Marubayashi, S., Heguy, A., Garcia-Manero, G., et al. (2009) · Nature Genetics · doi:10.1038/ng.342 · Cited by 349
Myeloproliferative Neoplasms: A Contemporary Review
Tefferi, A., & Pardanani, A. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.89 · Cited by 342
MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2
Ding, L., Xu, Y., Zhang, W., Deng, Y., Si, M., Du, Y., Yao, H., Liu, X., Ke, Y., Si, J., et al. (2010) · Cell Research · doi:10.1038/cr.2010.79 · Cited by 341
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome
Bercovich, D., Ganmore, I., Scott, L. M., Wainreb, G., Birger, Y., Elimelech, A., Shochat, C., Cazzaniga, G., Biondi, A., Basso, G., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61341-0 · Cited by 337
Making sense of cancer genomic data
Chin, L., Hahn, W. C., Getz, G., & Meyerson, M. (2011) · Genes & Development · doi:10.1101/gad.2017311 · Cited by 336
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
Flex, E., Petrangeli, V., Stella, L., Chiaretti, S., Hornakova, T., Knoops, L., Ariola, C., Fodale, V., Clappier, E., Paoloni, F., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072182 · Cited by 334
Self-citationVerstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W. N., Miller, C. B., Silver, R. T., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.115840 · Cited by 334
Oh, S. T., Simonds, E. F., Jones, C., Hale, M. B., Goltsev, Y., Gibbs, K. D., Merker, J. D., Zehnder, J. L., Nolan, G. P., & Gotlib, J. (2010) · Blood · doi:10.1182/blood-2010-02-270108 · Cited by 330
Tefferi, A., & Vainchenker, W. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8711 · Cited by 327
Self-citationTheocharides, A., Boissinot, M., Girodon, F., Garand, R., Teo, S.-S., Lippert, E., Talmant, P., Tichelli, A., Hermouet, S., & Skoda, R. C. (2007) · Blood · doi:10.1182/blood-2006-12-062125 · Cited by 326
The molecular regulation of Janus kinase (JAK) activation
Babon, J. J., Lucet, I. S., Murphy, J. M., Nicola, N. A., & Varghese, L. N. (2014) · Biochemical Journal · doi:10.1042/bj20140712 · Cited by 326
Abdel-Wahab, O., Manshouri, T., Patel, J., Harris, K., Yao, J., Hedvat, C., Heguy, A., Bueso-Ramos, C., Kantarjian, H., Levine, R. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3783 · Cited by 326
Mesa, R. A., Verstovsek, S., Cervantes, F., Barosi, G., Reilly, J. T., Dupriez, B., Levine, R., Le Bousse-Kerdiles, M.-C., Wadleigh, M., Campbell, P. J., et al. (2007) · Leukemia Research · doi:10.1016/j.leukres.2006.12.002 · Cited by 322
Weniger, M. A., Melzner, I., Menz, C. K., Wegener, S., Bucur, A. J., Dorsch, K., Mattfeldt, T., Barth, T. F. E., & Möller, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209151 · Cited by 322
Tefferi, A., Lasho, T. L., Abdel-Wahab, O., Guglielmelli, P., Patel, J., Caramazza, D., Pieri, L., Finke, C. M., Kilpivaara, O., Wadleigh, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.113 · Cited by 318
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Walters, D. K., Mercher, T., Gu, T.-L., O'Hare, T., Tyner, J. W., Loriaux, M., Goss, V. L., Lee, K. A., Eide, C. A., Wong, M. J., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.002 · Cited by 317
Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D. G., & Lodish, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509714102 · Cited by 316
Kleppe, M., Kwak, M., Koppikar, P., Riester, M., Keller, M., Bastian, L., Hricik, T., Bhagwat, N., McKenney, A. S., Papalexi, E., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0736 · Cited by 315
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
Kang, M. R., Kim, M. S., Oh, J. E., Kim, Y. R., Song, S. Y., Seo, S. I., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2009) · International Journal of Cancer · doi:10.1002/ijc.24379 · Cited by 313
Portal vein thrombosis: Insight into physiopathology, diagnosis, and treatment
Ponziani, F. R. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i2.143 · Cited by 312
The Structure of the GM-CSF Receptor Complex Reveals a Distinct Mode of Cytokine Receptor Activation
Hansen, G., Hercus, T. R., McClure, B. J., Stomski, F. C., Dottore, M., Powell, J., Ramshaw, H., Woodcock, J. M., Xu, Y., Guthridge, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.05.053 · Cited by 311
Megakaryocyte development and platelet production
Deutsch, V. R., & Tomer, A. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06215.x · Cited by 311
Metadata
- Authors
- James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J. L., Constantinescu, S. N., Casadevall, N., & Vainchenker, W.
- Venue
- Nature
- Published
- 2005-03-27
- Volume
- 434
- Issue
- 7037
- Pages
- 1144-1148
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2049145190
- Cited by
- 3,544
- References
- 28
- FWCI
- 106.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.